http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006047114-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_05a203d85ee01909eaf728dc16f0f6cb |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-52 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-02 |
| filingDate | 2005-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_33fc28d052259110ea5c6e6ccf02dae0 |
| publicationDate | 2006-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2006047114-A1 |
| titleOfInvention | Azabicyclic amine histamine-3 receptor antagonists |
| abstract | This invention is directed to compounds of the formula I n nas defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a method of treatment of a disorder or condition that may be treated by antagonizing histamine H3 receptors, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above, and a method of treatment of a disorder or condition selected from the group consisting of depression, mood disorders, schizophrenia, anxiety disorders, Alzheimer's disease, attention-deficit disorder (ADD), attention-deficit hyperactivity disorder (ADHD), psychotic disorders, sleep disorders, obesity, dizziness, epilepsy, motion sickness, respiratory diseases, allergy, allergy-induced airway responses, allergic rhinitis, nasal congestion, allergic congestion, congestion, hypotension, cardiovascular disease, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastrointestinal tract, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2945534-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11274082-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10154988-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2012095040-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010130944-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10624875-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3610890-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8697883-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102459207-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11458149-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11760728-B2 |
| priorityDate | 2004-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1058.